



## **At BIOS SCHOTT to present a variety of glass substrates for use in biotechnology**

**Specialty glass and in-house micro-structuring technology for top quality substrates / NEXTERION® products now also pre-scribed to final format**

*San Francisco, CA & Mainz, Germany, January 30, 2014* – **The international technology group and specialty glass expert SCHOTT offers a broad portfolio of glass substrates with customized features for use in the growing field of life sciences, for instance, microfluidics and next-generation sequencing. The glass types D263® T eco, MEMPax®, BOROFLOAT® and B270®i offer the customer a choice between different product characteristics and material thicknesses to best suit the needs of the individual applications. These products as well as NEXTERION® substrates will be on display at BIOS from February 1 to 2 (SCHOTT booth #8642).**

Microfluidics is on its way to becoming a main stream enabling technology for fields as diverse as medical diagnostics, life science research or drug delivery and synthesis. There are many applications which rely on highly complex microfluidic chips, and these chips can only be produced from high quality substrates. In such cases, polymer-based chips fail to provide the required level of precision or sophistication and the costs of silicon chips are very high. Therefore, glass-based chips are ideally suited for applications which rely on chip complexity such as high density or integrated sensing functionalities at a competitive price level.

“Not only do we at SCHOTT offer a portfolio of different well-known glass products for a maximum variety of uses, but we have also developed our own micro-structuring technology which allows us to apply structures under 100 microns in diameter to the glass substrates. We can process the borosilicate glass types D263® T eco, MEMPax® and BOROFLOAT® as well as the highly transparent ultra-white




crown glass B 270<sup>®</sup> i,” says Andreas Haedrich, Sales Director EMEA for SCHOTT Advanced Optics.

### **NEXTERION<sup>®</sup> substrates pre-scribed to final format**


SCHOTT now also offers its NEXTERION<sup>®</sup> slides and wafers for biotech applications pre-scribed to the final format, allowing for the substrates to be processed first and then efficiently broken to size in the final step. This results in easier handling and cost reductions especially for high quantities. Microarray applications are the foundation of NEXTERION<sup>®</sup> substrates, however, a diverse portfolio with customized solutions for life science and diagnostics complement the standard product range.

For more information visit

[http://www.schott.com/english/applications/healthcare\\_laboratory.html](http://www.schott.com/english/applications/healthcare_laboratory.html)



SCHOTT offers a broad portfolio of glass substrates with customized features for use in the growing field of life sciences, for instance, microfluidics. Photo: SCHOTT.



Pre-scribed NEXTERION® substrates for biotech applications can be processed first and then efficiently broken to size in the final step.  
Photo: SCHOTT.

Download link: <http://www.schott-pictures.net/presskit/225136.bios>

More press photographs: [www.schott-pictures.net](http://www.schott-pictures.net)

*SCHOTT is an international technology group with more than 125 years of experience in the areas of specialty glasses and materials and advanced technologies. SCHOTT ranks number one in the world with many of its products. Its core markets are the household appliance, pharmaceuticals, electronics, optics, solar power, transportation and architecture industries. The company is strongly committed to contributing to its customers' success and making SCHOTT an important part of people's lives with its high-quality products and intelligent solutions. SCHOTT is committed to managing its business in a sustainable manner and supporting its employees, society and the environment. The SCHOTT Group maintains close proximity to its customers with manufacturing and sales units in 35 different countries. Its workforce of around 16,000 employees generated worldwide sales of approximately 2 billion euros for the 2011/2012 fiscal year. SCHOTT AG, with its headquarters in Mainz, Germany, is owned by the Carl Zeiss Foundation.*

**Media contact:**

SCHOTT AG  
Dr. Haike Frank  
Public Relations Manager  
Phone: +49 (0)6131/66-4088  
e-mail: [haike.frank@schott.com](mailto:haike.frank@schott.com)  
Internet: [www.schott.com](http://www.schott.com)